Literature DB >> 22924613

Higher TSH level is a risk factor for differentiated thyroid cancer.

Hee Kyung Kim1, Jee Hee Yoon, Soo Jeong Kim, Jin Seong Cho, Sun-Seog Kweon, Ho-Cheol Kang.   

Abstract

OBJECTIVES: Higher thyroid-stimulating hormone (TSH) levels are associated with differentiated thyroid cancers (DTC). To validate this association, we compared TSH levels obtained from euthyroid patients with DTC with TSH levels from controls in the general population. DESIGN AND PATIENTS: The case group included 1759 patients with DTC, who underwent thyroid surgery at Chonnam National University Hwasun Hospital. The control group (n = 1548), who had participated in the Thyroid Disease Prevalence Study were used as a healthy control group. The subjects were divided into four groups of similar size according to their TSH levels, with the first quartile used as a reference group.
RESULTS: The mean TSH level of the case group was significantly higher than the mean TSH level of the control group (1.95 ± 0.9 mIU/l vs 1.62 ± 0.8 mIU/l, P < 0.001), and was associated with DTC risk. Multiple logistic regression, after controlling for age, gender and the presence of a family history of thyroid cancer, showed that the odds ratios and 95% confidence intervals for the second, third and fourth quartiles of TSH levels were 1.27 (1.03-1.57), 1.55 (1.25-1.92) and 2.21 (1.78-2.74) respectively. No significant differences were observed in mean TSH levels in patients with different tumour stages and tumour sizes.
CONCLUSION: Having a high TSH level within the normal range is an independent risk factor for DTC, and may contribute to the initiation of thyroid carcinogenesis. TSH levels in patients with thyroid nodules may be used as diagnostic adjuncts for the identification of high-risk patients, who require further investigation and/or surgical intervention.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22924613     DOI: 10.1111/cen.12027

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  22 in total

1.  Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma.

Authors:  Iwao Sugitani; Yoshihide Fujimoto; Keiko Yamada
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.

Authors:  Huang Huang; Jennifer Rusiecki; Nan Zhao; Yingtai Chen; Shuangge Ma; Herbert Yu; Mary H Ward; Robert Udelsman; Yawei Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-04       Impact factor: 4.254

4.  Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies.

Authors:  Li Xu; Matthias Port; Stefano Landi; Federica Gemignani; Monica Cipollini; Rossella Elisei; Lilia Goudeva; Jörg Andreas Müller; Kai Nerlich; Giovanni Pellegrini; Christoph Reiners; Cristina Romei; Robert Schwab; Michael Abend; Erich M Sturgis
Journal:  Thyroid       Date:  2014-05-05       Impact factor: 6.568

5.  Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Ozdemir; Cevdet Aydın; Nagihan Bestepe; Serap Ulusoy; Nuran Sungu; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2018-01-27       Impact factor: 3.633

6.  Cyp24a1 Attenuation Limits Progression of BrafV600E -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720.

Authors:  Minjing Zou; Essa Y Baitei; Huda A BinEssa; Futwan A Al-Mohanna; Ranjit S Parhar; René St-Arnaud; Shioko Kimura; Catrin Pritchard; Ali S Alzahrani; Abdullah M Assiri; Brian F Meyer; Yufei Shi
Journal:  Cancer Res       Date:  2017-02-27       Impact factor: 12.701

7.  KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.

Authors:  Minjing Zou; Essa Y Baitei; Roua A Al-Rijjal; Ranjit S Parhar; Futwan A Al-Mohanna; Shioko Kimura; Catrin Pritchard; Huda BinEssa; Azizah A Alanazi; Ali S Alzahrani; Mohammed Akhtar; Abdullah M Assiri; Brian F Meyer; Yufei Shi
Journal:  Lab Invest       Date:  2015-07-06       Impact factor: 5.662

8.  Thyroid cancer risk is not increased in diabetic patients.

Authors:  Chin-Hsiao Tseng
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

9.  Grand challenges in cancer endocrinology: endocrine related cancers, an expanding concept.

Authors:  Antonino Belfiore; Claire M Perks
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-08       Impact factor: 5.555

10.  The Effect of ThyroidߚStimulating Hormone on Stage of Differentiated Thyroid Carcinoma.

Authors:  Laya Soleimanisardoo; Mohsen Rouhani; Fatemeh Soleymani Sardoo; Mohammad Hossein Gozashti
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.